Clinical Trials Logo

Clinical Trial Summary

The UKGPCS was set up to find genetic alterations which occur in patients who have prostate cancer. A man's risk of developing prostate cancer increases if he has a first-degree relative (father or brother) who was diagnosed with prostate cancer at a young age. This is why we are looking for men who are affected at a young age or who have a family history of prostate cancer, since it is more probable that these prostate cancers are due to an inherited genetic cause rather than an environmental cause. We also ask all men who come to the Royal Marsden Hospital to be treated for prostate cancer if they would like to take part in the study so that we can also look to see if we find genetic alterations in older men, and those who do not have a family history of prostate cancer.

Clinical Trial Description

The study is divided into two parts: 1. The Study at The Royal Marsden NHS Foundation Trust, London and Sutton: The study will be offered to every patient attending the prostate clinics at The Royal Marsden NHS Foundation Trust, London and Sutton. This is called 'The Systematic Study'. Patients are approached in the clinic and are given an information sheet and the study is also explained verbally. They are asked for 18ml of blood and asked to fill out a family history and epidemiological questionnaire. Those who have not had any treatment will also be asked for 18ml blood for serum and plasma marker studies. Those patients with one relative affected with PrCa where one is ≤ 65 years at diagnosis or a total of 3 or more relatives with PrCa at any age, will be asked if their relatives can be approached to be asked to give a blood sample for DNA analysis for PrCa predisposition genes and tumour samples for molecular analyses for PrCa predisposition and behaviour as outlined above. Where relatives with PrCa are deceased, pathology records and tumour blocks will be requested after obtaining details of where they were treated via the index case. Consent Consent will be sought prospectively from living individuals accrued into the study from January 2006 to access medical records and tumour blocks. This study has been active since 1992 and all blood samples have informed consent for PrCa predisposition gene studies. Outside tumour blocks and pathological samples have informed consent for molecular studies. Many of The Royal Marsden NHS Foundation Trust PrCa tumour samples also have consent under a clause in the operation consent form in use at that time that 'material removed may be used for research purposes'. Some tissue was collected from local hospitals under the auspices of the previous protocol and the consent form did not explicitly state separate consent for the use of tissue at that time, although it was part of the approved protocol. Many patients are now deceased. It is therefore proposed that tissue and medical record data collected retrospectively will be analysed anonymously with no results fed back to patients as this would not impact upon their care. An exception is results from the studies on blood where findings in PrCa predisposition genes could have implications for relatives. Those patients who are still living who have previously taken part in the study from 1992 until the present and who have not taken part in the environmental questionnaire part of the study will be invited to take part in this part of the study. New consent will be obtained for this. 2. The Study at Collaborative Centres throughout the UK. Many of these are via the NCRN network. This is conducted as for the Study at The Royal Marsden except the study is explained verbally and then if the patient is interested, their details are given to the study office by confidential fax and the study office sends the patient an information sheet and consent form. Furthermore, the only groups of patients eligible for this part of the study are (a) men with PrCa presenting at a young age (≤ 60 years) or (b) PrCa in first-degree related pairs where one is ≤ 65 years at diagnosis or (c) a total of 3 or more relatives with PrCa at any age The two parts (1) and (2) are now called the UKGPCS (UK Genetic Prostate Cancer Study). There are currently over 300 collaborators UK-wide participating under the auspices of the previous protocol (previously, The Cancer Research UK/British Prostate Group//British Association of Urological Surgeons Section of Oncology and NCRN Familial Prostate Cancer Study). Proposed analyses on the samples The samples will be used to find PrCa predisposition genes using linkage and other analyses. These investigations are solely for research to find a prostate cancer-predisposing gene and no results would be conveyed to the patients until such a gene(s) had been found. If such a gene(s) is found, then no patient will have genetic testing for abnormalities in such a gene without prior genetic counselling and this would be on a newly taken blood sample. Only those patients who wish (as stated on their consent form) to be informed of research findings will be contacted. If this occurs more than 6 months after the last contact with the patient, this would be via the GP. Data will be correlated with medical records and treatment outcome to find genetic alterations that are associated with prostate cancer development and/or prognosis. Tumour material will be collected and stored at -70oC in freezer space currently available at The Institute of Cancer Research. Tumour will also be stored in RNA later and paraffin embedded tumour will be made into tissue microarrays and sections cut. This will be used for molecular biology analysis. Cases and their relatives may be flagged by the cancer registry to confirm a diagnosis of prostate cancer, a date of death and cause of death. This will be done via the Medical Research Information Service (MRIS), using records maintained by The NHS Information Centre and the NHS Central Register. Clinical details are collected routinely as part of the medical care and clinical follow up record on patients with prostate cancer and these include disease parameters (e.g. stage, grade) and treatment outcome (e.g. survival data, side effects of treatment). We will also request follow-up data, approximately 2 years after the patient has consented, to record any relapse, treatment and survival data that has occurred since diagnosis. We will link the genetic findings with these clinical data to try to identify genetic markers of disease parameters (e.g. those which predict for poorer prognosis or worse late toxicity from treatments such as radiotherapy). These data would be analysed anonymously after linking the clinical and genetic datasets. No results would be feedback to participants. We will supply anonymised data from this to an EU dataset (Genepi study). This would only be to a central database managed under the auspices of GCP and would only be anonymised data. No individual would be identifiable to the holders of the Genepi database. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT01737242
Study type Observational
Source Institute of Cancer Research, United Kingdom
Contact Rosalind A Eeles, FRCP FRCR
Phone 02086613642
Email [email protected]
Status Recruiting
Start date January 1993
Completion date December 2022

See also
  Status Clinical Trial Phase
Recruiting NCT04081636 - Prostate Biopsy, Transrectal vs. Transperineal: Efficacy and Complications N/A
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Recruiting NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Active, not recruiting NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Active, not recruiting NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A
Active, not recruiting NCT00499421 - Evaluation of Intraprostatic Fiducial Markers For External Beam Radiation Therapy
Recruiting NCT03668652 - Focal Prostate Ablation Versus Radical Prostatectomy N/A
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A
Recruiting NCT04219059 - MR Radiomic Features in Prostate Cancer
Recruiting NCT04060589 - ReIMAGINE Prostate Cancer Risk
Recruiting NCT03700099 - Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide Phase 2
Recruiting NCT04249154 - Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer Phase 2
Recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Terminated NCT00953576 - Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer Phase 1/Phase 2